On Monday, November 13, 2021, New York Assemblyman Pat Burke introduced medical psilocybin legislation. The “purpose or general idea of bill” provides a good summary: this legislation would “create psilocybin service centers to provide innovative treatment options for ailments such as PTSD, depression, alcohol dependency, anxiety, among others.”
The bill echoes two separate pieces of controlled substance legislation: (1) Oregon’s legalization of psilocybin (a topic we have written about extensively (here, here and here, to list a few)); and (2) New York’s Marijuana Regulation and Taxation Act (MRTA), which is another topic we have written about extensively (see here, here and here, to start).
A few key points from the bill:
Several License Types
Like the MRTA, this medical psilocybin legislation includes several licenses types with a similar path for licensure:
Registration as a psilocybin service center, which will include preparation, administration, and integration sessions all of which are guided and monitored by a psilocybin service facilitator. Registered organizations, which will be allowed to acquire, possess, manufacture, sell, deliver, transport, distribute or dispense psilocybin. Psilocybin research license, which will allow the testing potency, conducting clinical investigations, researching efficacy and safety, and agricultural research. Psilocybin service facilitator license, which will